Study ID: NRG-LU005
Limited-stage small cell lung cancer: a phase II/III randomized study of chemoradiation vs. chemoradiation plus atezolizumab
Researchers seeks patients who have been diagnosed with limited-stage small cell lung cancer for a clinical research study. This trial is testing treatment with chemotherapy, radiation therapy and the medication Tecenriq® (atezolizumab), or chemotherapy and radiation therapy without the medication.
Atezolizumab is an immunotherapy drug currently FDA approved to treat certain types of cancer. However, atezolizumab has not yet been approved to treat small cell lung cancer. It is believed that immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread.
Each participant in this trial receives three cycles of intravenous chemotherapy over a 21-day period and radiation therapy. One group also receives atezolizumab intravenously on day one or two of each chemotherapy cycle. Cycles repeat every three weeks for one year.
The primary outcomes being measured in this study are progression-free and overall survival.
Eligible patients are those with limited-stage (Tx, T1-T4, N0-3, M0) small cell lung cancer.
- Must have been diagnosed with limited-stage small cell lung cancer; no metastatic disease detected
- Must be able to undergo intravenous treatments and radiation therapy
- Must not have been previously treated with an immunotherapy agent
- Other inclusion/exclusion criteria apply